IL219674B - Methods to prevent crystallization of pharmaceutical substances with polymer coating - Google Patents

Methods to prevent crystallization of pharmaceutical substances with polymer coating

Info

Publication number
IL219674B
IL219674B IL219674A IL21967412A IL219674B IL 219674 B IL219674 B IL 219674B IL 219674 A IL219674 A IL 219674A IL 21967412 A IL21967412 A IL 21967412A IL 219674 B IL219674 B IL 219674B
Authority
IL
Israel
Prior art keywords
crystallisation
pharmaceuticals
preventing
polymer film
polymer
Prior art date
Application number
IL219674A
Other languages
English (en)
Hebrew (he)
Other versions
IL219674A0 (en
Inventor
Muller Walter
Josef Leonhard Johannes
Original Assignee
Lts Lohmann Therapie Systeme Ag
Muller Walter
Josef Leonhard Johannes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43877347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL219674(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Systeme Ag, Muller Walter, Josef Leonhard Johannes filed Critical Lts Lohmann Therapie Systeme Ag
Publication of IL219674A0 publication Critical patent/IL219674A0/en
Publication of IL219674B publication Critical patent/IL219674B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
IL219674A 2009-11-12 2012-05-08 Methods to prevent crystallization of pharmaceutical substances with polymer coating IL219674B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009052972A DE102009052972A1 (de) 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
PCT/EP2010/006535 WO2011057714A2 (fr) 2009-11-12 2010-10-26 Procédé pour empêcher la cristallisation de substances pharmaceutiques dans un film polymère

Publications (2)

Publication Number Publication Date
IL219674A0 IL219674A0 (en) 2012-07-31
IL219674B true IL219674B (en) 2018-10-31

Family

ID=43877347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219674A IL219674B (en) 2009-11-12 2012-05-08 Methods to prevent crystallization of pharmaceutical substances with polymer coating

Country Status (17)

Country Link
US (2) US8932665B2 (fr)
EP (1) EP2498762B1 (fr)
JP (3) JP5837883B2 (fr)
KR (1) KR101685736B1 (fr)
CN (2) CN102770128A (fr)
AR (1) AR079028A1 (fr)
AU (1) AU2010318328B2 (fr)
BR (1) BR112012011297B8 (fr)
CA (1) CA2780787C (fr)
DE (1) DE102009052972A1 (fr)
EA (1) EA025301B1 (fr)
ES (1) ES2594765T3 (fr)
IL (1) IL219674B (fr)
MX (1) MX2012005511A (fr)
PL (1) PL2498762T3 (fr)
TW (1) TWI489998B (fr)
WO (1) WO2011057714A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204173A1 (en) 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
KR102363218B1 (ko) 2017-12-19 2022-02-14 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
JP7399633B2 (ja) * 2019-06-14 2023-12-18 株式会社大石膏盛堂 経皮吸収型製剤の製造方法
DE102019117870B3 (de) * 2019-07-02 2020-11-26 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066534B2 (ja) 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5662928A (en) 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
AU1120097A (en) * 1995-12-01 1997-06-27 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
CA2302411C (fr) * 1997-09-02 2007-01-30 Novartis Ag Procede ameliore destine a empecher la formation de cristaux dans un dispositif d'administration transdermique de scopolamine
DE19954936A1 (de) 1999-11-16 2001-05-17 Bayer Ag Verfahren zur Herstellung von Benzofuranonoximen
DE60008136T2 (de) 1999-11-23 2004-09-09 Aderis Pharmaceuticals, Inc. Verbessertes verfahren zur herstellung von n-substituierte aminotetraline
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4641394B2 (ja) 2004-08-06 2011-03-02 リンテック株式会社 経皮吸収型製剤の製造方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US8344165B2 (en) 2007-05-30 2013-01-01 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
WO2009053697A1 (fr) 2007-10-26 2009-04-30 Pliva Hrvatska D.O.O. Formes polymorphes du chlorhydrate de (s)-rotigotine
WO2009063171A1 (fr) 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Nouveaux sels de rotigotine
EP2215072B1 (fr) 2007-11-28 2015-09-02 UCB Pharma GmbH Forme polymorphique de rotigotine
US20110087042A1 (en) * 2008-02-04 2011-04-14 Matrix Laboratories Limited Crystalline oxybutynin and process for preparing the same
IT1392387B1 (it) 2008-09-26 2012-03-02 Solmag S P A Ora Fidia Farmaceutici S P A Processo per la preparazione di rotigotina
AU2009302853B2 (en) 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
WO2010073124A2 (fr) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Procédé de préparation de rotigotine très pure ou d'un sel pharmaceutiquement acceptable de celle-ci
EP2201941A1 (fr) 2008-12-29 2010-06-30 UCB Pharma GmbH Technologie de fabrication de pavé

Also Published As

Publication number Publication date
BR112012011297B8 (pt) 2021-05-25
AU2010318328B2 (en) 2015-01-22
JP6161668B2 (ja) 2017-07-12
CN106619578A (zh) 2017-05-10
EP2498762A2 (fr) 2012-09-19
DE102009052972A1 (de) 2011-09-15
US8932665B2 (en) 2015-01-13
IL219674A0 (en) 2012-07-31
AR079028A1 (es) 2011-12-21
JP5837883B2 (ja) 2015-12-24
US20120213912A1 (en) 2012-08-23
CA2780787C (fr) 2017-11-07
JP2017149758A (ja) 2017-08-31
ES2594765T3 (es) 2016-12-22
WO2011057714A2 (fr) 2011-05-19
JP6374566B2 (ja) 2018-08-15
MX2012005511A (es) 2012-06-14
CN102770128A (zh) 2012-11-07
CA2780787A1 (fr) 2011-05-19
US20140046279A1 (en) 2014-02-13
KR20120115258A (ko) 2012-10-17
JP2016028078A (ja) 2016-02-25
JP2013510805A (ja) 2013-03-28
TWI489998B (zh) 2015-07-01
BR112012011297A2 (pt) 2016-04-12
BR112012011297B1 (pt) 2020-12-15
CN106619578B (zh) 2021-10-01
EP2498762B1 (fr) 2016-09-07
WO2011057714A3 (fr) 2011-07-07
EA025301B1 (ru) 2016-12-30
US9408809B2 (en) 2016-08-09
EA201270618A1 (ru) 2013-01-30
PL2498762T3 (pl) 2017-02-28
AU2010318328A1 (en) 2012-05-31
TW201124156A (en) 2011-07-16
KR101685736B1 (ko) 2016-12-12

Similar Documents

Publication Publication Date Title
IL219674B (en) Methods to prevent crystallization of pharmaceutical substances with polymer coating
EP2403670A4 (fr) Films organiques structurés
PL2631613T3 (pl) Sposób i układ do kalibrowania układu dozowania płynu
EP2479780A4 (fr) Appareil de formation de film
GB0908300D0 (en) Polyester films
EP2330148A4 (fr) Film d'acide polylactique
EP2436722A4 (fr) Film mince autoportant de polymère
PL2454040T3 (pl) Urządzenie do formowania cienkich warstw i sposób stosowania takiego urządzenia
EP2583994A4 (fr) Film d'acide polylactique
GB0915687D0 (en) Polyester films
HK1149088A1 (en) Film
EP2644643A4 (fr) Film ou feuille d'acide polylactique
EP2428592A4 (fr) Procédé de fabrication d'un film de zircone
PL2516134T3 (pl) Wstępnie rozciągnięta folia polietylenowa
EP2490251A4 (fr) Couche mince de fixation de puce
EP2502953A4 (fr) Film stratifié
EP2544221A4 (fr) Film cristallin, dispositif et procédés de production de film cristallin et de dispositif
EP2117953A4 (fr) Films d'emballage
EP2552690A4 (fr) Film texturé et procédé de fabrication de ce dernier
PL2363286T3 (pl) Folia opakowaniowa, opakowanie i sposób wytwarzania takiego opakowania
HK1187862A1 (en) Energy-shielding plastics film
EP2669320A4 (fr) Film en résine d'acide polylactique
EP2589482A4 (fr) Dispositif de production de film et procédé de production
AU325184S (en) Dissolving film packaging
ZA201107683B (en) Label film

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed